Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00897793 · ClinicalTrials.gov registry record

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
25
Enrollment target
3
Study locations

NCT00897793 is a study of Breast Cancer and Prostate Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 25 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00897793, a study of Breast Cancer and Prostate Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
25 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.

Interventions

  • RADIATION radiation therapy
  • PROCEDURE venipuncture

Study Locations (3)

Tennessee

  • Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
  • Vanderbilt-Ingram Cancer Center at Franklin - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2006-01
Est. Completion 2010-07

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

What the Registry Record Tells You About NCT00897793

The ClinicalTrials.gov registry entry for NCT00897793 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.

NCT00897793 reports 3 study locations spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00897793 about?

NCT00897793 is a clinical study titled "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer". RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is ...

What is the current status of trial NCT00897793?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2006-01. Estimated completion is 2010-07.

What conditions does trial NCT00897793 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer.

What interventions are being tested in trial NCT00897793?

The interventions under investigation include: radiation therapy (RADIATION), venipuncture (PROCEDURE).

Who is sponsoring clinical trial NCT00897793?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00897793 being conducted?

This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.